Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Updates in Anthracycline-Mediated Cardiotoxicity
Canan G. Nebigil, Laurent Désaubry
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 171

Showing 1-25 of 171 citing articles:

Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management
Pushkar Singh Rawat, Aiswarya Jaiswal, Amit Khurana, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 139, pp. 111708-111708
Open Access | Times Cited: 567
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention
Anchit Bhagat, Eugenie S. Kleinerman
Advances in experimental medicine and biology (2020), pp. 181-192
Closed Access | Times Cited: 159
Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation
Danlei Li, Xiaoman Liu, Wenhu Pi, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 144
Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician
Ekaterina Podyacheva, Е. А. Кушнарева, А. А. Карпов, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 107
Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents
Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, et al.
Journal of Chemotherapy (2024) Vol. 36, Iss. 8, pp. 623-653
Closed Access | Times Cited: 18
Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 309-332
Closed Access | Times Cited: 132
Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1
Zhenzhu Sun, Wenqiang Lu, Na Lin, et al.
Biochemical Pharmacology (2020) Vol. 175, pp. 113888-113888
Closed Access | Times Cited: 123
DNA topoisomerases as molecular targets for anticancer drugs
Kamila Buzun, Anna Bielawska, Krzysztof Bielawski, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2020) Vol. 35, Iss. 1, pp. 1781-1799
Open Access | Times Cited: 93
LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation
Xiaoman Liu, Danlei Li, Wenhu Pi, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109379-109379
Open Access | Times Cited: 53
Signaling Pathways Underlying Anthracycline Cardiotoxicity
Valentina Sala, Angela Della Sala, Emilio Hirsch, et al.
Antioxidants and Redox Signaling (2020) Vol. 32, Iss. 15, pp. 1098-1114
Closed Access | Times Cited: 50
Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats
Hayder M. Al‐kuraishy, Hany Akeel Al-Hussaniy, Ali I. Al‐Gareeb, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 37
Dapagliflozin protects against doxorubicin-induced cardiotoxicity by restoring STAT3
Wei‐Ting Chang, Jhih‐Yuan Shih, Yu‐Wen Lin, et al.
Archives of Toxicology (2022) Vol. 96, Iss. 7, pp. 2021-2032
Closed Access | Times Cited: 30
Protective effect of cafestol against doxorubicin-induced cardiotoxicity in rats by activating the Nrf2 pathway
Sara A. Al-Kenany, Nada N. Al-Shawi
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
The role of ginseng derivatives against chemotherapy-induced cardiotoxicity: A systematic review of non-clinical studies
Arezoo Moini Jazani, AmirAhmad Arabzadeh, Hamed Haghi‐Aminjan, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 18
An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
Sicong Xie, Yuwei Sun, Xuan Zhao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Exosomes miRNA-499a-5p targeted CD38 to alleviate anthraquinone induced cardiotoxicity: experimental research
Chunhua Ma, Zhaocong Yang, Jing Wang, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 4, pp. 1992-2006
Open Access | Times Cited: 6
Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond?
Jiaming Lei, Jianbao Yang, Cuiyu Bao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Cytotoxic T cells drive doxorubicin-induced cardiac fibrosis and systolic dysfunction
Abraham L. Bayer, Marìa Zambrano, Sasha Smolgovsky, et al.
Nature Cardiovascular Research (2024) Vol. 3, Iss. 8, pp. 970-986
Closed Access | Times Cited: 6
Photo-Electro Active Nanocomposite Silk Hydrogel for Spatiotemporal Controlled Release of Chemotherapeutics: An In Vivo Approach toward Suppressing Solid Tumor Growth
Ankit Gangrade, Basveshwar Gawali, Jadi Praveen Kumar, et al.
ACS Applied Materials & Interfaces (2020) Vol. 12, Iss. 25, pp. 27905-27916
Closed Access | Times Cited: 49
Doxorubicin cardiomyopathy is ameliorated by acacetin via Sirt1‐mediated activation of AMPK/Nrf2 signal molecules
Wei‐Yin Wu, Yukai Cui, Yi‐Xiang Hong, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 20, pp. 12141-12153
Open Access | Times Cited: 49
Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases
Dong Wang, Redouane Tabti, Sabria Elderwish, et al.
Cellular and Molecular Life Sciences (2020) Vol. 77, Iss. 18, pp. 3525-3546
Open Access | Times Cited: 48
Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity
Verena Schwach, Rolf H. Slaats, Robert Passier
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 44
An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity
Miguel Godinho de Oliveira Anjos, Marta Fontes Oliveira, Vera Marisa Costa, et al.
Life Sciences (2021) Vol. 280, pp. 119760-119760
Closed Access | Times Cited: 40
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications
Agata Bikiewicz, Maciej Banach, Stephan von Haehling, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 4, pp. 2397-2418
Open Access | Times Cited: 34
Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues
Roshni Bhatnagar, Neal M. Dixit, Eric H. Yang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top